Thank you for the question.
From Telus Health's perspective, it's important to note, as I mentioned earlier, that our main responsibility in this case was to deliver the technology, the managed service and the highway.
I will add, though, to your question, that, as we too saw that the adoption was not high—through the fact that the number of transactions that were going through this highway was much lower than expected—we convened in 2021 a clinical advisory board, which is something we do to assess our products, in general, in the market. This was an advisory board that comprised those prescribers, those individuals. We got their feedback as to why the adoption, from their perspective, was not as high as expected. We took that feedback from them and provided it to Canada Health Infoway, as an opportunity to provide improvements to the standards that were put in place.